Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;23(5):450-452.
doi: 10.1111/cns.12693. Epub 2017 Mar 30.

Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®)

Alejandro Romero  1 , Esther Parada  2   3 , Laura González-Lafuente  2   3 , Victor Farré-Alins  2   3 , Eva Ramos  1 , Ramón Cacabelos  4 , Javier Egea  2   3
Affiliations

Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®)

Alejandro Romero et al. CNS Neurosci Ther. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Neuroprotective effect of Atremorine against oxidative stress and 6‐OHDA. SH‐SY5Y neuroblastoma cells were preincubated with Atremorine for 24 h prior to the addition of rote/oligo (A) and 6‐OHDA (B). Neuroprotective effects of Atremorine were evaluated in striatum and hippocampal slices subjected to 6‐OHDA (C) and oxygen and glucose deprivation (D), respectively; cell viability was measured as MTT reduction. Data are expressed as means+SEM of at least four different cell batches in triplicate. ***P<.001, with respect to control; ## P<.01, # P<.05, in comparison with toxic stimuli
Figure 2
Figure 2
Antiinflammatory effect of Atremorine in BV2 microglial cells. Panel (A) shows the protocol used to elicit inflammation. Microglia BV2 cells were treated with increasing concentrations of LPS in the absence or the presence of Atremorine for 24 h. Panel (B) shows Atremorine reduction of nitrite release elicited by LPS, measured as percentage of NO release. Panel (C) shows photomicrographs (original magnification 20×) of nontreated BV2 microglia, LPS‐treated (D) and Atremorine‐treated cells (E). Panel (F) shows statistics of the effect of Atremorine on activated phenotype elicited by LPS treatment. Data are expressed as means+SEM of at least four different cell batches in triplicate. ***P<.001, with respect to control; ### P<.001, ## P<.01, # P<.05, in comparison with toxic stimuli
See this image and copyright information in PMC

References

    1. Savica R, Grossardt BR, Bower JH, et al. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73:981‐989. - PMC - PubMed
    1. Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochem Biophys Acta. 2009;1792:676‐687. - PMC - PubMed
    1. Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139:325‐337. - PubMed
    1. Cacabelos R, Fernández‐Novoa L, Alejo R, et al. E‐PodoFavalin‐15999 (Atremorine®)‐induced dopamine response in parkinson's disease: pharmacogenetics‐related effects. J Genom Med Pharmacogenomics. 2016;1:1‐26.
    1. Carrera I, Fernández‐Novoa L, Sampedro C, et al. Dopaminergic neuroprotection with atremorine in Parkinson's disease. Curr Med Chem. 2017. (in press). - PubMed

Publication types

MeSH terms

LinkOut - more resources